Denali Therapeutics Inc. (DNLI) has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million. The voucher was granted by the U.S. FDA in May 2026 following approval of AVLAYAH (tividenofusp alfa-eknm), the first therapy to cross the blood-brain barrier for the treatment of Hunter syndrome.
The company stated that proceeds from the sale will strengthen its balance sheet and support continued investment in its pipeline of therapies for neurodegenerative and lysosomal storage diseases. Denali emphasized that the transaction aligns with its strategy to advance innovative programs while maintaining financial flexibility.
The PRV sale is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.
DNLI has traded between $12.58 and $24.20 over the past year. The stock closed Wednesday's trading at $23.49, up 7.11%. In pre-market trading the stock is at $23.78, up 1.24%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.